account(BUSINESS WIRE) -- 4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, has presented novel data on the mechanism of action of vidofludimus, an oral inhibitor of interleukin-17...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to 4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-i"B Pathways
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account